Oberursel Taunus

Researchers are evaluating the real-world effectiveness of nemolizumab in treating moderate-to-severe Prurigo Nodularis (PN) in adults. This non-interventional, prospective, multicenter study focuses on physician assessments and patient-reported outcomes over approximately 12 months in routine clinical settings. The study aims to measure improvements using both investigator and patient evaluations at Month 6. Treatment with nemolizumab (Nemluvio) is decided by the participant's physician before enrollment, with no additional visits or tests beyond usual care. Visit schedules follow standard medical practice rather than study requirements. A sub-study in Germany and the UK involves daily remote completion of Peak Pruritus Numerical Rating Scale (PP NRS) and Sleep Disturbance NRS from Day -1 to Day 14 without clinic visits. Participants will be involved in routine clinical visits where physician assessments and patient-reported outcomes are collected. The main outcomes measured include the Investigator Global Assessment of chronic Prurigo (IGA-CPG stage) and Peak Pruritus Numerical Rating Scale at 6 months. Data collection relies on standard practice, with no extra procedures, and monitoring occurs throughout the study duration of about one year.

Researchers are evaluating the real-world effectiveness of nemolizumab for treating moderate-to-severe atopic dermatitis (AD) in adolescents and adults. This study is a prospective, multicenter, non-interventional trial that aims to measure treatment outcomes through physician assessments and patient-reported outcomes over approximately 12 months. The goal is to understand how nemolizumab works in routine clinical practice, focusing on physician evaluations and patient experiences at Month 6. Treatment with nemolizumab is determined solely by the participant's physician before joining the study, with no extra visits, procedures, or lab tests beyond standard care. The study does not define a specific visit schedule; instead, visits follow routine medical practice to collect data systematically. A sub-study in Germany and the UK will have participants complete daily questionnaires on itch severity, sleep disturbance, and pain from Day -1 to Day 14 remotely, without requiring clinic visits. Participants will be involved in routine clinical visits where physician assessments and patient-reported outcome measures will be gathered. Key outcomes measured include the Investigator Global Assessment (IGA) and the Peak Pruritus Numerical Rating Scale (PP NRS) at Month 6. The study observes participant responses and safety under normal care conditions, with data collection lasting about a year to evaluate nemolizumab's effectiveness in everyday treatment settings.